Ren Da

Renda Biosciences is a biotechnology company headquartered in Shanghai, China, specializing in the development of innovative small molecule therapeutics through targeted protein degradation (TPD) technology. The company leverages its proprietary Renda-TPD platform to design and optimize PROTACs (Proteolysis Targeting Chimeras) and other degraders for challenging-to-treat diseases, particularly in oncology and immunology. Renda's approach focuses on degrading disease-causing proteins that are traditionally considered undruggable by conventional inhibitors. By utilizing the body's natural ubiquitin-proteasome system, the company aims to provide more effective and durable treatment options for patients. The firm is led by a team of industry veterans with extensive experience in drug discovery and development within the global pharmaceutical landscape.